Latest Industry News & Trends
Market Scope provides comprehensive coverage of the ophthalmic market. Our news stories are a combination of public and proprietary content ranging from coverage of international meetings, surgeon survey results and trends, analysis of company financial reports and public medical registries, press releases, and interviews with executives. Register today to receive free weekly email updates, our top data chart, surgeon poll results, and much more. Locked content can be accessed through a subscription to our ophthalmic industry newsletters.
Recently Added News
US FDA Approves Expanded Label for Izervay to Extend Treatment for GA Beyond 12 Months
Japan’s Astellas Pharma announced Feb. 12 that the US FDA had approved expanded labeling for Izervay (avacincaptad pegol intravitreal solution) for geographic atrophy (GA), extending the allowed du...
2024 and Quarterly Ophthalmic Revenue Roundup for Regeneron, Carl Zeiss Meditec, Hoya, and STAAR
Regeneron, of Tarrytown, New York, reported Feb. 4 that its 2024 US revenue for Eylea 2 mg (aflibercept 2 mg) and Eylea HD (aflibercept 8 mg) totaled nearly $5.97 billion, a 1 percent increase over...
EssilorLuxottica Acquires Canadian Retinal Camera Maker Cellview Imaging
Eyewear conglomerate EssilorLuxottica announced Feb. 11 that it had acquired Cellview Imaging, a Canadian startup specializing in ultra-widefield retinal diagnostics. Cellview’s WRI-1 fundus camera...
Acelyrin to Merge with Alumis in All-Stock Transaction
Acelyrin, which was developing lonigutamab, a subcutaneous treatment candidate for thyroid eye disease (TED), announced Feb. 6 that it would merge with Alumis in an all-stock transaction. The combi...
US FDA Grants RMAT Designation for Beacon’s XLRP Gene Therapy Candidate
Beacon Therapeutics announced Jan. 28 that the US FDA had granted regenerative medicine advanced therapy (RMAT) designation to laru-zova (laruparetigene zovaparvovec, also known as AGTC-501), Beaco...
Ocugen’s RP Gene Therapy Candidate Gains Advanced Therapy Status in Europe
Ocugen announced Feb. 3 that European regulators had granted advanced therapy medicinal product status to OCU400, a modifier gene therapy candidate for retinitis pigmentosa (RP). OCU400 (AAV-NR2E3)...
Kala Bio’s CEO Resigns; President, COO Takes Over as Interim
Kala Bio announced Feb. 12 that its chief executive officer, Mark Iwicki, had resigned, and that Todd Bazemore, Kala’s president and chief operating officer, had been appointed interim CEO, effecti...
Bausch + Lomb Rules Out Sale After Concluding Bid Process
Bausch + Lomb announced Feb. 6 that it had ruled out a sale of the company, after exploring the option in its bid for a full separation from parent company Bausch Health. “Taking Bausch + Lomb priv...
Appeals Court Upholds Injunctions Blocking Eylea Biosimilars from Samsung Bioepis and Formycon
In a victory for Regeneron, the US Court of Appeals for the Federal Circuit issued a ruling Jan. 29 upholding preliminary injunctions that block Samsung Bioepis and Formycon from launching their ap...
2024 Ophthalmic Revenue Roundup for Roche, AbbVie, Novartis
Swiss company Roche reported Jan. 29 that global sales of Vabysmo for 2024 were CHF 3.86 billion ($4.25 billion, converted Jan. 29, 2025), a 63.6 percent increase (+68 percent cc) over CHF 2.36 bil...
US FDA Approves Genentech’s Susvimo Refillable Implant for DME
Genentech, a member of the Roche Group, announced Feb. 4 that the US FDA had approved Susvimo, a refillable ranibizumab implant, for diabetic macular edema (DME). The company said Susvimo is now av...
Australian Regulators Approve Apellis’ Syfovre for Geographic Atrophy
Apellis Pharmaceuticals announced Jan. 27 that Australia’s Therapeutic Goods Administration had approved Syfovre (intravitreal pegcetacoplan) for the every-other-month treatment of adult patients w...
Past News Stories
Harrow, Cencora Partner to Improve Drug Access for Retina Specialists, Patients
Drugmaker Harrow reported Jan. 27 that it had partnered with Cencora to launch a program called “Harrow Cares,” with the goal of making Harrow products iHeezo and Triesence more accessible and affo...
Iantrek Appoints Adam Szaronos as Chief Executive Officer
Iantrek announced Feb. 4 that it had appointed Adam Szaronos as its new chief executive officer. Szaronos succeeds company founder and innovator Sean Ianchulev, MD, MPH, who will remain as chairman...
Aflibercept Biosimilar Candidate from Amgen Gains Positive CHMP Opinion
Europe’s Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion Jan. 30 for an aflibercept (Eylea) biosimilar from Amgen, under the names Pavblu and Skojoy. The biosimilar ...
Chinese Regulators Accept Marketing Application for Zhaoke’s Low-Dose Atropine Drop for Myopia
Vyluma announced Jan. 29 that China’s National Medical Products Administration had accepted the marketing application from Zhaoke Ophthalmology for NVK002 (low-dose atropine 0.01%) targeting myopia...
2024 Ophthalmic Revenue Roundup for J&J Vision, Lumibird, and Nicox
Johnson & Johnson reported Jan. 22 that its full year 2024 global surgical vision revenue was $1.41 billion, a 3.2 percent increase (+4.3 percent cc) over $1.37 billion in 2023. Revenue was down 3....
Norlase Receives US Clearance and CE Marking for Lynx Pattern Scanning Laser Indirect Ophthalmoscope
Norlase announced Jan. 27 the commercial launch of the Lynx, which the company says is the world’s first laser indirect ophthalmoscope with integrated pattern scanning capabilities for photocoagula...
Outlook Reports Final Results of Lytenava Trial, Plans BLA Resubmission in Q1-2025
Outlook Therapeutics reported Jan. 16 the final results of the NORSE EIGHT trial of ONS-5010 (Lytenava), an ophthalmic formulation of bevacizumab for wet age-related macular degeneration (AMD). ONS...
Aurion Plans to Launch IPO; Alcon Loses Court Bid to Stop Move
A judge will allow Aurion Biotech, of Seattle, Washington, to go ahead with its planned initial public offering after rejecting shareholder Alcon’s arguments to prevent the move. The decision was h...
NovaBay Gains Shareholder Approval to Sell Eye Care Business
NovaBay, of Emeryville, California, reported Jan. 23 that it had completed the sale of its eye care business to PRN Physician Recommended Nutriceuticals for $11.5 million. The sale includes all the...
Retrospective Study Finds Link Between IVT Injections, Cataract Surgery Complications
Researchers from the Byers Eye Institute at Stanford Health Care in Palo Alto, California, have found that cataractpatients with prior intravitreal (IVT) injections face more complications after ca...
US FDA Grants Rare Pediatric Designation to MeiraGTx’ LCA1 Gene Therapy Candidate
MeiraGTx, with offices in London and New York, announced Jan. 22 that the US FDA had granted rare pediatric disease designation to its AAV8-RK-RetGC gene therapy candidate for Leber congenital amau...
US FDA Grants Fast Track Status to Nacuity’s Oral RP Candidate
Nacuity Pharmaceuticals announced Jan. 21 that the US FDA had granted fast track designation to NPI-001 (N-acetylcysteine amide) tablets, Nacuity’s oral retinitis pigmentosa (RP) treatment candidat...
Want to Read the Full Article?
Already Have an Account?
Register A Corporate Account
A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.